Clinical Trial Update: The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib [Phase 1]

View source ↗

Summary

This Phase 1 study assessed how a high-fat versus low-fat breakfast affects regorafenib pharmacokinetics; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastrointestinal Stromal Tumor
• Hepatocellular Carcinoma

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: Bayer | Conditions: Dietary Fats, Pharmacokinetics | Phase 1 | Status: COMPLETED